RV7 Stock Overview
A biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Halozyme Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.39 |
| 52 Week High | US$58.18 |
| 52 Week Low | US$30.78 |
| Beta | 1.29 |
| 11 Month Change | 1.00% |
| 3 Month Change | -18.64% |
| 1 Year Change | 26.64% |
| 33 Year Change | 49.45% |
| 5 Year Change | 162.09% |
| Change since IPO | 2,018.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| RV7 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.0% | -0.7% | -0.02% |
| 1Y | 26.6% | -17.2% | 8.2% |
Return vs Industry: RV7 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: RV7 exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| RV7 volatility | |
|---|---|
| RV7 Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: RV7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RV7's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 373 | Helen Torley | halozyme.com |
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.
Halozyme Therapeutics, Inc. Fundamentals Summary
| RV7 fundamental statistics | |
|---|---|
| Market cap | €5.99b |
| Earnings (TTM) | €376.89m |
| Revenue (TTM) | €909.75m |
15.9x
P/E Ratio6.6x
P/S RatioIs RV7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RV7 income statement (TTM) | |
|---|---|
| Revenue | US$947.36m |
| Cost of Revenue | US$249.60m |
| Gross Profit | US$697.75m |
| Other Expenses | US$305.29m |
| Earnings | US$392.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.08 |
| Gross Margin | 73.65% |
| Net Profit Margin | 41.43% |
| Debt/Equity Ratio | 332.3% |
How did RV7 perform over the long term?
See historical performance and comparison